614 related articles for article (PubMed ID: 20672322)
21. PCA3: from basic molecular science to the clinical lab.
Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
[TBL] [Abstract][Full Text] [Related]
22. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
23. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
24. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
[TBL] [Abstract][Full Text] [Related]
25. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
26. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
[TBL] [Abstract][Full Text] [Related]
27. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
28. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.
Sokoll LJ; Ellis W; Lange P; Noteboom J; Elliott DJ; Deras IL; Blase A; Koo S; Sarno M; Rittenhouse H; Groskopf J; Vessella RL
Clin Chim Acta; 2008 Mar; 389(1-2):1-6. PubMed ID: 18061575
[TBL] [Abstract][Full Text] [Related]
29. Quadriplex model enhances urine-based detection of prostate cancer.
Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966
[TBL] [Abstract][Full Text] [Related]
30. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting.
Shappell SB; Fulmer J; Arguello D; Wright BS; Oppenheimer JR; Putzi MJ
Urology; 2009 Feb; 73(2):363-8. PubMed ID: 18995890
[TBL] [Abstract][Full Text] [Related]
31. [Value of urinary PCA3 test for prostate cancer diagnosis].
Vlaeminck-Guillem V; Ruffion A; Andre J
Prog Urol; 2008 May; 18(5):259-65. PubMed ID: 18538269
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
33. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M; Schalken JA
J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
35. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice.
Schilling D; Hennenlotter J; Munz M; Bökeler U; Sievert KD; Stenzl A
Urol Int; 2010; 85(2):159-65. PubMed ID: 20424427
[TBL] [Abstract][Full Text] [Related]
36. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
[TBL] [Abstract][Full Text] [Related]
38. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
39. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
40. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
